Dexcom

DXCM Health Care Market cap $32.0B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026

Revenue$1.31B +13% year over year

Gross profit$0.83B 63% margin

Operating profit$0.32B 24% margin

Net profit$0.25B 19% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.31	100%	+13%
US	0.93	71%	+11%
Non US	0.38	29%	+19%
Cost of revenue	−0.48	37%
Gross profit	0.83	63% margin	+4pp
R&D	−0.15	12%	−1pp
SG&A	−0.36	27%	−1pp
Operating profit	0.32	24% margin	+6pp
Tax	−0.07
Net profit	0.25	19% margin	+3pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.19	100%	+15%
US	0.83	70%	+11%
Non US	0.36	30%	+26%
Cost of revenue	−0.44	37%
Gross profit	0.75	63% margin	+6pp
R&D	−0.15	12%	−2pp
SG&A	−0.35	30%	−1pp
Operating profit	0.26	21% margin	+9pp
Other income, net	0.01
Tax	−0.07
Net profit	0.20	17% margin	+7pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.26	100%	+13%
US	0.89	71%	+11%
Non US	0.37	29%	+18%
Cost of revenue	−0.47	37%
Gross profit	0.79	63% margin	+4pp
R&D	−0.15	12%	−1pp
SG&A	−0.32	25%	−4pp
Operating profit	0.32	26% margin	+9pp
Other income, net	0.02
Tax	−0.07
Net profit	0.27	21% margin	+8pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.21	100%	+22%
US	0.85	70%	+21%
Non US	0.36	30%	+22%
Cost of revenue	−0.48	40%
Gross profit	0.73	60% margin	+1pp
R&D	−0.16	13%	−1pp
SG&A	−0.33	27%	−3pp
Operating profit	0.24	20% margin	+5pp
Other income, net	0.11
Tax	−0.07
Net profit	0.28	23% margin	+10pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.04	100%	+12%
US	0.75	72%	+15%
Non US	0.29	28%	+7%
Cost of revenue	−0.45	43%
Gross profit	0.59	57% margin	−4pp
R&D	−0.15	14%	−1pp
SG&A	−0.31	30%	−5pp
Operating profit	0.13	13% margin	+2pp
Other income, net	0.02
Tax	−0.05
Net profit	0.11	10% margin	−6pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026 Operating margin 24% Net profit $0.25B	Apr 1 – Jun 30, 2026	Jul 30, 2026	$1.31B	+13%	24%	$0.25B	19%
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 30, 2026 Operating margin 21% Net profit $0.20B	Jan 1 – Mar 31, 2026	Apr 30, 2026	$1.19B	+15%	21%	$0.20B	17%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 12, 2026 Operating margin 26% Net profit $0.27B	Oct 1 – Dec 31, 2025	Feb 12, 2026	$1.26B	+13%	26%	$0.27B	21%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 30, 2025 Operating margin 20% Net profit $0.28B	Jul 1 – Sep 30, 2025	Oct 30, 2025	$1.21B	+22%	20%	$0.28B	23%
Q1 FY25 Jan 1 – Mar 31, 2025 reported May 1, 2025 Operating margin 13% Net profit $0.11B	Jan 1 – Mar 31, 2025	May 1, 2025	$1.04B	+12%	13%	$0.11B	10%